Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program#United_States#Cambridge#COVID-19#Decoy_Therapeutics#DCOY-CoV
Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program
Decoy Therapeutics has shared groundbreaking preclinical data suggesting a weekly intranasal dosing regimen for its DCOY-CoV initiative, maintaining drug efficacy for up to a week.
third-news.com
September 29, 2026 at 11:40 AM
Decoy Therapeutics Unveils Promising Preclinical Data for Once-Weekly Intranasal Dosing in DCOY-CoV Program#United_States#Cambridge#COVID-19#Decoy_Therapeutics#DCOY-CoV
Decoy Therapeutics Corrects Press Release Regarding Warrant Inducement Transaction#USA#Houston#biotechnology#Decoy_Therapeutics#DCOY
Decoy Therapeutics Corrects Press Release Regarding Warrant Inducement Transaction
Decoy Therapeutics, Inc. recently corrected a statement regarding warrant inducement transactions, clarifying the terms of new warrants issued.
third-news.com
September 22, 2026 at 10:19 PM
Decoy Therapeutics Corrects Press Release Regarding Warrant Inducement Transaction#USA#Houston#biotechnology#Decoy_Therapeutics#DCOY
Decoy Therapeutics Appoints Patricia Gauthier to Board of Directors to Enhance Antiviral Development#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#Patricia_Gauthier
Decoy Therapeutics Appoints Patricia Gauthier to Board of Directors to Enhance Antiviral Development
Decoy Therapeutics has nominated Patricia Gauthier for its Board of Directors, bringing extensive biotech leadership to enhance its antiviral initiatives.
third-news.com
June 3, 2026 at 12:23 PM
Decoy Therapeutics Appoints Patricia Gauthier to Board of Directors to Enhance Antiviral Development#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#Patricia_Gauthier
Decoy Therapeutics Secures Up to $21 Million Through Private Placement Financing for Antiviral Development#United_States#Houston#biotechnology#Decoy_Therapeutics#D-MAVs
Decoy Therapeutics Secures Up to $21 Million Through Private Placement Financing for Antiviral Development
Decoy Therapeutics has announced a private placement financing deal expected to raise up to $21 million to advance its antiviral therapies into clinical trials.
third-news.com
June 27, 2026 at 12:16 AM
Decoy Therapeutics Secures Up to $21 Million Through Private Placement Financing for Antiviral Development#United_States#Houston#biotechnology#Decoy_Therapeutics#D-MAVs
Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal to Further Antiviral Innovations#United_States#Houston#Warrant_Inducement#Decoy_Therapeutics#D-MAVs
Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal to Further Antiviral Innovations
Decoy Therapeutics, a pioneering firm in antiviral technology, announces a $3.85 million through a warrant inducement transaction. This funding will accelerate their antiviral research.
third-news.com
September 22, 2026 at 5:01 PM
Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal to Further Antiviral Innovations#United_States#Houston#Warrant_Inducement#Decoy_Therapeutics#D-MAVs
Decoy Therapeutics Expands Anti-Viral Strategy with FDA Pathway and Non-Dilutive Funding#USA#Cambridge#Decoy_Therapeutics#Antivirals#D-MAVs
Decoy Therapeutics Expands Anti-Viral Strategy with FDA Pathway and Non-Dilutive Funding
Decoy Therapeutics is innovating its anti-viral programs under the FDA Animal Rule while seeking non-dilutive funding to expedite drug development.
third-news.com
September 22, 2026 at 11:45 AM
Decoy Therapeutics Expands Anti-Viral Strategy with FDA Pathway and Non-Dilutive Funding#USA#Cambridge#Decoy_Therapeutics#Antivirals#D-MAVs
Decoy Therapeutics Enters Partnership with hVIVO to Propel Antiviral Research Forward#United_States#Cambridge#Decoy_Therapeutics#hVIVO#D-MAV
Decoy Therapeutics Enters Partnership with hVIVO to Propel Antiviral Research Forward
Decoy Therapeutics has partnered with hVIVO to advance its innovative D-MAV candidates into clinical studies, marking a significant step in antiviral research.
third-news.com
June 1, 2026 at 11:15 AM
Decoy Therapeutics Enters Partnership with hVIVO to Propel Antiviral Research Forward#United_States#Cambridge#Decoy_Therapeutics#hVIVO#D-MAV
Decoy Therapeutics Appoints MIT's Brad Pentelute as Scientific Advisory Board Chair to Advance Antiviral Innovations#United_States#Cambridge#Decoy_Therapeutics#IMP³ACT#Brad_Pentelute
Decoy Therapeutics Appoints MIT's Brad Pentelute as Scientific Advisory Board Chair to Advance Antiviral Innovations
Decoy Therapeutics has appointed MIT Professor Brad Pentelute as Chair of its Scientific Advisory Board, enhancing its antiviral research leadership.
third-news.com
May 26, 2026 at 12:37 PM
Decoy Therapeutics Appoints MIT's Brad Pentelute as Scientific Advisory Board Chair to Advance Antiviral Innovations#United_States#Cambridge#Decoy_Therapeutics#IMP³ACT#Brad_Pentelute
Decoy Therapeutics Welcomes Patricia Gauthier to Board, Strengthening Leadership for Innovative Antiviral Development#USA#Cambridge#Decoy_Therapeutics#D-MAVs#Patricia_Gauthier
Decoy Therapeutics Welcomes Patricia Gauthier to Board, Strengthening Leadership for Innovative Antiviral Development
Decoy Therapeutics announces the election of Patricia Gauthier to its Board of Directors, enhancing its commitment to pioneering antiviral innovations and market expansion.
third-news.com
July 15, 2026 at 2:05 PM
Decoy Therapeutics Welcomes Patricia Gauthier to Board, Strengthening Leadership for Innovative Antiviral Development#USA#Cambridge#Decoy_Therapeutics#D-MAVs#Patricia_Gauthier
Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals#USA#Cambridge#Decoy_Therapeutics#IMP3ACT_platform#Designable_Multi-Antivirals
Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals
Decoy Therapeutics has expanded its intellectual property portfolio, now encompassing seven patent families, enhancing its position in the antiviral space.
third-news.com
August 3, 2026 at 1:25 PM
Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals#USA#Cambridge#Decoy_Therapeutics#IMP3ACT_platform#Designable_Multi-Antivirals
Decoy Therapeutics Unveils Promising Antiviral Advancements Against Ebola Zaire Threat#United_States#Cambridge#Decoy_Therapeutics#D-MAV#Ebola_Zaire
Decoy Therapeutics Unveils Promising Antiviral Advancements Against Ebola Zaire Threat
Decoy Therapeutics announced significant progress with its D-MAV platform, showcasing potential against Ebola Zaire and other high-threat viruses. Discover their innovative approach.
third-news.com
July 27, 2026 at 1:10 PM
Decoy Therapeutics Unveils Promising Antiviral Advancements Against Ebola Zaire Threat#United_States#Cambridge#Decoy_Therapeutics#D-MAV#Ebola_Zaire
Decoy Therapeutics' CEO to Discuss Innovations in Antiviral Development at hVIVO Capital Markets Day in London#London#United_Kingdom#Decoy_Therapeutics#D-MAVs#Rick_Pierce
Decoy Therapeutics' CEO to Discuss Innovations in Antiviral Development at hVIVO Capital Markets Day in London
Decoy Therapeutics' CEO Rick Pierce will share insights on early clinical development at hVIVO's Capital Markets Day in London. The focus will be on antiviral innovations.
third-news.com
June 8, 2026 at 12:18 PM
Decoy Therapeutics' CEO to Discuss Innovations in Antiviral Development at hVIVO Capital Markets Day in London#London#United_Kingdom#Decoy_Therapeutics#D-MAVs#Rick_Pierce
Decoy Therapeutics Announces Participation in Key Peptide Conferences in Boston#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#IMP³ACT
Decoy Therapeutics Announces Participation in Key Peptide Conferences in Boston
Decoy Therapeutics will showcase its innovative approach to peptide therapeutics at two major conferences in Boston, discussing advancements in antiviral design.
third-news.com
April 27, 2026 at 1:09 PM
Decoy Therapeutics Announces Participation in Key Peptide Conferences in Boston#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#IMP³ACT
Decoy Therapeutics Accelerates Path to Clinical Development in Antiviral Innovations#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#IMP³ACT
Decoy Therapeutics Accelerates Path to Clinical Development in Antiviral Innovations
Decoy Therapeutics is navigating an active phase, charting its clinical development in antiviral treatments. Key achievements and future plans highlight its rapid momentum.
third-news.com
April 9, 2026 at 1:05 PM
Decoy Therapeutics Accelerates Path to Clinical Development in Antiviral Innovations#United_States#Cambridge#Decoy_Therapeutics#D-MAVs#IMP³ACT
Decoy Therapeutics Achieves Nasdaq Compliance After Minimum Bid Price Requirement#USA#NASDAQ#Cambridge,_Massachusetts#Decoy_Therapeutics#Minimum_Bid
Decoy Therapeutics Achieves Nasdaq Compliance After Minimum Bid Price Requirement
Decoy Therapeutics, Inc. has successfully regained compliance with Nasdaq's Minimum Bid Price Requirement, ensuring its continued listing on the exchange.
third-news.com
April 2, 2026 at 2:10 PM
Decoy Therapeutics Achieves Nasdaq Compliance After Minimum Bid Price Requirement#USA#NASDAQ#Cambridge,_Massachusetts#Decoy_Therapeutics#Minimum_Bid
Decoy Therapeutics Partners with Quantori to Enhance AI-Driven Peptide Design via Google Cloud#United_States#Cambridge#Google_Cloud#Decoy_Therapeutics#Quantori
Decoy Therapeutics Partners with Quantori to Enhance AI-Driven Peptide Design via Google Cloud
Decoy Therapeutics announces a strategic collaboration with Quantori, supported by Google Cloud funding, to significantly improve peptide design speed and efficacy in antiviral research.
third-news.com
March 11, 2026 at 12:55 PM
Decoy Therapeutics Partners with Quantori to Enhance AI-Driven Peptide Design via Google Cloud#United_States#Cambridge#Google_Cloud#Decoy_Therapeutics#Quantori
Decoy Therapeutics Plans a Reverse Stock Split to Comply with Nasdaq Listing Rule#USA#Cambridge#Biopharmaceutical#Decoy_Therapeutics#DCOY
Decoy Therapeutics Plans a Reverse Stock Split to Comply with Nasdaq Listing Rule
Decoy Therapeutics Inc. announces a 1-for-12 reverse stock split, aiming for compliance with Nasdaq’s minimum bid price requirement.
third-news.com
March 5, 2026 at 1:49 PM
Decoy Therapeutics Plans a Reverse Stock Split to Comply with Nasdaq Listing Rule#USA#Cambridge#Biopharmaceutical#Decoy_Therapeutics#DCOY
Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service#United_States#Cambridge#Investor_Relations#Webull#Decoy_Therapeutics
Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service
Decoy Therapeutics has joined the Webull Corporate Connect Service to improve communication and transparency with shareholders, enhancing investor engagement.
third-news.com
February 11, 2026 at 2:35 PM
Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service#United_States#Cambridge#Investor_Relations#Webull#Decoy_Therapeutics
Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026#USA#biopharmaceuticals#Cambridge#Webull#Decoy_Therapeutics
Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026
Join Decoy Therapeutics on February 10, 2026, for an enlightening session at Webull's Corporate Connect Webinar Series. Explore their advancements in antiviral therapeutics!
third-news.com
February 5, 2026 at 3:18 PM
Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026#USA#biopharmaceuticals#Cambridge#Webull#Decoy_Therapeutics
Decoy Therapeutics Unveils Innovative Global Access Commitment for Peptide-Conjugate Antivirals#Decoy_Therapeutics#peptide-conjugate#antiviral
Decoy Therapeutics Unveils Innovative Global Access Commitment for Peptide-Conjugate Antivirals
Decoy Therapeutics engages investors through a virtual segment, presenting its Global Access Commitment Agreement to enhance antiviral accessibility worldwide.
third-news.com
February 4, 2026 at 2:27 PM
Decoy Therapeutics Unveils Innovative Global Access Commitment for Peptide-Conjugate Antivirals#Decoy_Therapeutics#peptide-conjugate#antiviral
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access#USA#Gates_Foundation#Cambridge#Decoy_Therapeutics#IMP3ACT_platform
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access
Decoy Therapeutics has announced a collaboration with the Gates Foundation to create a scalable manufacturing platform for peptide-conjugate antivirals aimed at improving global access, especially in low-income countries.
third-news.com
January 13, 2026 at 1:50 PM
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access#USA#Gates_Foundation#Cambridge#Decoy_Therapeutics#IMP3ACT_platform
Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research#USA#Houston#Clinical_Trials#Salarius_Pharmaceuticals#Decoy_Therapeutics
Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research
Salarius Pharmaceuticals recently announced a $7 million underwritten public offering aimed at financing its clinical oncology programs and merger with Decoy Therapeutics.
third-news.com
November 11, 2025 at 3:48 PM
Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research#USA#Houston#Clinical_Trials#Salarius_Pharmaceuticals#Decoy_Therapeutics